My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

28.38 +0.10 (+0.35%)
Streaming Delayed Price Updated: 12:43 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Janux (JANX) R&D Soars Revenue Misses
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
The Top 5 Mid Cap Stocks Of 2024
These high-fliers are on the leading edge of innovation. 
Via Talk Markets
Topics Stocks / Equities
Navigating 10 Analyst Ratings For Janux Therapeutics
 
Via Benzinga
Why Janux Therapeutics Crushed the Market Today
Via The Motley Fool
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
 
Via Benzinga
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
S&P 500 Cools From Post-Election Record Highs
The Dow Jones Industrial Average is down triple digits this afternoon, as traders unpack this morning's jobs data. 
Via Talk Markets
Topics Stocks Stocks / Equities
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients. 
Via Benzinga
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Navigating 5 Analyst Ratings For Janux Therapeutics
 
Via Benzinga
Analyst Expectations For Janux Therapeutics's Future
 
Via Benzinga
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
The Latest Analyst Ratings For Janux Therapeutics
 
Via Benzinga
Analyst Ratings For Janux Therapeutics
 
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
 
Via Benzinga
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden. 
Via The Motley Fool
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming. 
Via InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.